肌萎缩侧索硬化临床试验及功能终点与体液生物标志物的解读:综述
本综述讨论肌萎缩侧索硬化(ALS)临床试验的最新进展,包括限制入排标准后在小样本短周期试验中观察到疗效信号、ALS功能评定量表修订版仍是最常用主要结局指标、血神经丝蛋白水平可预测预后但当前知识尚不支持其作为主要结局指标,以及结果普遍性、监管审批所需数据和应答者分析价值等问题。
要点
- 限制入排标准可招募进展速度特定的同质性人群,但结果普遍性仍是担忧。
- ALS功能评定量表修订版仍是最常用的主要结局指标,综述讨论了其使用创新。
- 血神经丝蛋白水平可预测预后和反映生物学效应,但当前知识不支持作为主要结局指标。
核心结论
- 现在有可能使用特定入组标准招募进展速度特定的同质性患者人群,这可能影响未来的试验。
- 有限人群结果的普遍性仍是担忧。
- 临床结局仍是最合适的主要结局指标,但随着对体液标志物与临床终点关联的了解增多,反映生物学重要过程的体液标志物将更为重要。
- 应答者分析等分析策略的获益仍不确定。
研究设计与样本
- 综述,讨论近期关键性研究对ALS临床试验相关主题的启示。
主要发现
- 通过限制入组和排除标准,近期试验招募了与既往研究不同的人群。
- 这导致在比先前认为可行更小、更短的试验中观察到疗效信号。
- 此类试验引发了关于结果普遍性的问题。
- 临床结果不明确的小型试验也引发了关于监管审批所需数据的问题。
- ALS功能评定量表修订版仍是最常用的主要结局指标,本综述讨论了其使用的创新。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Clinical trial activity in amyotrophic lateral sclerosis (ALS) is dramatically increasing; as a result, trial modifications have been introduced to improve efficiency, outcome measures have been reassessed, and considerable discussion about the level of data necessary to advance a drug to approval has occurred. This review discusses what recent pivotal studies can teach the community about these topics. OBSERVATIONS: By restricting inclusion and exclusion criteria, recent trials have enrolled populations distinct from previous studies. This has led to efficacy signals being observed in studies that are smaller and shorter than was thought feasible previously. However, such trials raise questions about generalizability of results. Small trials with equivocal clinical results also raise questions about the data necessary to lead to regulatory approval. The ALS Functional Rating Scale-Revised remains the most commonly used primary outcome measure; this review discusses innovations in its use. Blood neurofilament levels can predict prognosis in ALS and may be a sensitive indicator of biologic effect; current knowledge does not yet support its use as a primary outcome. CONCLUSIONS AND RELEVANCE: It is now possible to use specific inclusion criteria to recruit a homogeneous patient population progressing at a specific rate; this will likely impact trials in the future. Generalizability of results on limited populations remains a concern. Although clinical outcomes remain the most appropriate primary outcome measures, fluid markers reflecting biologically important processes will assume more importance as more is learned about the association between such markers and clinical end points. The benefit of use of analytic strategies, such as responder analyses, is still uncertain.
引用
- Shefner JM, Bedlack R, Andrews JA, et al. Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A Review. JAMA Neurol. 2022. PMID: 36251310. doi:10.1001/jamaneurol.2022.3282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。